生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | The methylation of lysine 9 on histone H3 by the histone methyltransferase G9a is a modification related to aberrant silencing of tumor suppressor genes. BRD9539 is the potential active form of BRD4770, a histone methyltransferase inhibitor in cells. BRD9539 dose-dependently inhibited G9a activity with an IC50 value of 6.3μM, but its inhibitory effect decreased with increasing S-adenosylmethionine concentrations. BRD9539 also blocked PRC2 activity with a similar IC50 value but had no inhibitory effect against SUV39H1 or DNMT1 up to 40μM. BRD9539 showed no activity in cell-based assays, probably due to impaired cell permeability. BRD9539 at 5 or 10μM exhibited no inhibitory activity towards 100 kinases related to cell-cycle regulation and cancer cell biology, and 16 other chromatin-modifying enzymes[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.50mL 0.50mL 0.25mL |
12.52mL 2.50mL 1.25mL |
25.03mL 5.01mL 2.50mL |
参考文献 |
---|